Nurix shareholders elect all director nominees; say-on-pay passes with 58.5% support

Nurix Therapeutics, Inc.

All three Class III directors elected: Sands (97.1%), Kunkel (87.5%), Silva (86.2%) of votes cast.
Ratification of PricewaterhouseCoopers as auditor received 99.9% of votes cast for.
Non-binding advisory say-on-pay approval: 19.9M for, 12.5M against, 1.6M abstain (58.5% support).
Notable 12.5% of votes withheld for Kunkel and 13.8% for Silva, indicating shareholder dissent.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2023. at the 2023-05-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-04

Exact text from the filing

Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Abstentions Broker Non-Votes 39,212,140 10,575 15,196 — The stockholders ratified the appointment

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors: Arthur T. Sands, M.D., Ph.D., Lori A. Kunkel, M.D., Paul M. Silva, each to serve a three-year term expiring at the 2026 annual meeting. at the 2023-05-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-04

Exact text from the filing

Proposal 1. Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 33,080,351 971,642 5,185,918 Lori A. Kunkel, M.D. 29,782,567 4,269,426 5,185,918 Paul M. Silva 29,337,363 4,714,630 5,185,918 Each of the three nominees for director was elected

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2023-05-04 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-04

Exact text from the filing

Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers Votes For Votes Against Abstentions Broker Non-Votes 19,907,448 12,499,830 1,644,715 5,185,918 The stockholders approved

View on SEC.gov

Browse all shareholder votes →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-23-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.